Table 1 Selected microRNA-based clinical trials
Cancer type | Type of trial | Intervention or tissue type | Clinical application | Reference |
|---|---|---|---|---|
Hepatocellular or liver metastasis | Therapeutic | miR‐34 delivery (MRK-34) | Phase 1 toxicity trial | [7] |
Thyroid | Biomarker | Tissue (fine needle aspiration) | Diagnosis, chemoresponse | [8] |
Breast | Biomarker | Blood | Prognosis, surveillance, cardiotoxicity | [9] |
Breast | Biomarker | Tissue | Chemoresponse, diagnosis | [9] |
Glioma | Biomarker | Tissue | miR-10b levels in diagnosis and prognosis | [10] |
Leukemia | Biomarker | Blood | miR-155 as predictor of graft versus host disease | [11] |
Lung | Biomarker | Tissue | Chemoresponse | |
Neuroblastoma | Biomarker | Tissue | Prognosis, tumor classification | [12] |
Colon | Biomarker | Tissue | Disease stratification, chemoresponse | [13] |
Renal | Biomarker | Cell | Tissue chemoresponse | [14] |
Esophageal | Biomarker | Tissue | Predictor of response to zinc | |
Melanoma | Biomarker | Blood | Predictor of response to propranolol | [15] |